Cantargia AB
www.cantargia.comCantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.
Read more
Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers, entering phase I/IIa clinical development.
Read more
Country
City (Headquarters)
Lund
Industry
Employees
11-50
Founded
2010
Social
Employees statistics
View all employeesPotential Decision Makers
Vice President Biometrics
Email ****** @****.comPhone (***) ****-****Board Member
Email ****** @****.comPhone (***) ****-****Board Member
Email ****** @****.comPhone (***) ****-****Chief Operations Officer
Email ****** @****.comPhone (***) ****-****
Technologies
(19)
Reach decision makers at Cantargia AB
Free credits every month!
Cantargia AB FAQ
Lund, Sweden
Biotechnology Research
